Market News
Stay updated with the latest market trends, earnings, and economic indicators.
Stocks To Buy Today: Kush Bohra Recommends Aditya Birla Capital, IKS And More — Check Target Price
Technical analyst Kush Bohra shares his top picks for the day.
DIIs extend buying streak; FIIs post marginal inflows on June 23
Domestic institutional investors remained net buyers on June 23, extending their support for Indian equities, while FIIs posted marginal inflows. The institutional buying came despite a broad-based market sell-off that dragged benchmark indices sharply lower.
Aditya Birla Capital raises ₹4,000 crore from promoters, IFC via preferential share allotment
Aditya Birla Capital raised ₹4,000 crore via a preferential share allotment to promoters Grasim Industries and Suryaja Investments, and to IFC.
Explained - Why Jefferies prefers Bajaj Finance, Aditya Birla Capital over other NBFCs
Jefferies expects the sector to deliver healthy loan growth, easing credit costs and largely range-bound NIMs. While valuations have recovered from the lows seen during the recent geopolitical tensions, they remain broadly around long-term averages.
Aditya Birla Capital allots 11.23 cr equity shares on preferential basis
1. 8,08,94,331 equity shares of face value of Rs 10 each at an issue price of Rs 356.02 for an aggregate amount of Rs 2879.99 crore to Grasim Industries, the promoter of the company.
Rs 1.5 lakh crore behind 2025! Can Jio, NSE and other mega IPOs put 2026 on course for another record year?
India's primary market faces a significant fundraising gap to match last year's record. However, upcoming mega IPOs from Reliance Jio (Rs 35,000 crore) and NSE (Rs 25,000 crore), alongside SBI Mutual Fund (Rs 10,000 crore), could inject much-needed demand. Experts believe these established names can revive investor sentiment, but a broad-based revival hinges on sensible valuations and a steady pipeline of quality companies.
Aditya Birla Capital among 3 stocks flashing bullish signals, hinting at a possible uptrend
Three NSE midcap stocks, Escorts Kubota, Aditya Birla Capital and REC, featured on StockEdge’s White Marubozu scanner on June 22, signalling strong buying momentum and bullish technical sentiment.
Vodafone Idea raises Rs 1,182 crore from promoter Aditya Birla Group
Vodafone Idea secured Rs 1,182 crore from promoter Aditya Birla Group via warrants, a crucial step towards its Rs 1 lakh crore cash generation target. The company is banking on this, new loans, and tax refunds to meet its financial obligations over the next three years. Despite a recent net profit boost from statutory liability relief, operational losses persist, highlighting the urgent need for these funding initiatives.
Vodafone Idea gets ₹4,730 crore Aditya Birla Group backing through warrant issue
Vodafone Idea has approved the allotment of 430 crore warrants to promoter-group entity Suryaja Investments, paving the way for a potential ₹4,730 crore capital infusion. The company has already received ₹1,182.5 crore upfront, with the balance payable when the warrants are converted into equity shares over the next 18 months.
Street Signals: Technical charts point to further upside for Nifty
Indian stock markets are showing a positive outlook, with analysts predicting the Nifty could climb towards 24,300-24,600. Key support levels are identified around 23,700-23,900, encouraging investors to buy on dips. Several stocks, including Britannia Industries, Grasim Industries, Aditya Birla Capital, Premier Energies, Bharat Electronics, and Eternal, are highlighted as top picks for the week, with specific buy recommendations and targets.
Sun Pharma to acquire Innovcare Lifesciences for ₹271.2 crore
Acquisition of the Mumbai-based pharma, nutraceutical and cosmeceutical products company is aimed at strengthening Sun Pharma’s product portfolio.
Sun Pharma adds Innovcare to its fold in Rs 271.2 crore all-cash transaction
India's largest drugmaker, Sun Pharma, is set to acquire Mumbai-based Innovcare Lifesciences for approximately $28.7 million in an all-cash deal. This strategic move aims to bolster Sun Pharma's product offerings. Innovcare, which markets pharmaceutical drugs, nutraceuticals, and cosmeceuticals, reported steady revenue growth in recent fiscal years. The transaction, expected to conclude by July 2026, is a significant step for Sun Pharma's expansion.